

Chun Jen Liu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5364014/publications.pdf>

Version: 2024-02-01

335
papers

17,547
citations

18479

62
h-index

18647

119
g-index

341
all docs

341
docs citations

341
times ranked

12703
citing authors

#	ARTICLE	IF	CITATIONS
1	Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. <i>Hepatology International</i> , 2016, 10, 1-98.	4.2	1,908
2	Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. <i>Hepatology International</i> , 2012, 6, 531-561.	4.2	874
3	Decreased Incidence of Hepatocellular Carcinoma in Hepatitis B Vaccinees: A 20-Year Follow-up Study. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1348-1355.	6.3	534
4	Hepatitis B Virus Genotype and DNA Level and Hepatocellular Carcinoma: A Prospective Study in Men. <i>Journal of the National Cancer Institute</i> , 2005, 97, 265-272.	6.3	518
5	Metabolic Factors and Risk of Hepatocellular Carcinoma by Chronic Hepatitis B/C Infection: A Follow-up Study in Taiwan. <i>Gastroenterology</i> , 2008, 135, 111-121.	1.3	492
6	High Levels of Hepatitis B Surface Antigen Increase Risk of Hepatocellular Carcinoma in Patients With Low HBV Load. <i>Gastroenterology</i> , 2012, 142, 1140-1149.e3.	1.3	469
7	Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 70-85.	2.8	358
8	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 60-78.	17.8	330
9	The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo. <i>Molecular Therapy - Nucleic Acids</i> , 2014, 3, e186.	5.1	319
10	High Prevalence and Mapping of Pre-S Deletion in Hepatitis B Virus Carriers With Progressive Liver Diseases. <i>Gastroenterology</i> , 2006, 130, 1153-1168.	1.3	257
11	Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. <i>Hepatology</i> , 2013, 57, 441-450.	7.3	227
12	Peginterferon Alfa-2a Plus Ribavirin for the Treatment of Dual Chronic Infection With Hepatitis B and C Viruses. <i>Gastroenterology</i> , 2009, 136, 496-504.e3.	1.3	211
13	Familial Risk of Hepatocellular Carcinoma Among Chronic Hepatitis B Carriers and Their Relatives. <i>Journal of the National Cancer Institute</i> , 2000, 92, 1159-1164.	6.3	200
14	Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. <i>Journal of Hepatology</i> , 2004, 41, 659-666.	3.7	194
15	Long-term Effects of Hepatitis B Immunization of Infants in Preventing Liver Cancer. <i>Gastroenterology</i> , 2016, 151, 472-480.e1.	1.3	187
16	Serum Hepatitis B Surface Antigen Levels Predict Surface Antigen Loss in Hepatitis B e Antigen Seroconverters. <i>Gastroenterology</i> , 2011, 141, 517-525.e2.	1.3	184
17	Pegylated Interferon-2a plus Ribavirin for Treatment-Naive Asian Patients with Hepatitis C Virus Genotype 1 Infection: A Multicenter, Randomized Controlled Trial. <i>Clinical Infectious Diseases</i> , 2008, 47, 1260-1269.	5.8	177
18	Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1555-1560.	2.8	174

#	ARTICLE	IF	CITATIONS
19	Role of Hepatitis B Viral Load and Basal Core Promoter Mutation in Hepatocellular Carcinoma in Hepatitis B Carriers. <i>Journal of Infectious Diseases</i> , 2006, 193, 1258-1265.	4.0	163
20	Global Perspective on the Natural History of Chronic Hepatitis B: Role of Hepatitis B Virus Genotypes A to J. <i>Seminars in Liver Disease</i> , 2013, 33, 097-102.	3.6	154
21	Hepatitis C Virus Seromarkers and Subsequent Risk of Hepatocellular Carcinoma: Long-Term Predictors From a Community-Based Cohort Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 4587-4593.	1.6	150
22	Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage. <i>Journal of Hepatology</i> , 2009, 50, 958-968.	3.7	144
23	Hepatitis C Virus Infection and Increased Risk of Cerebrovascular Disease. <i>Stroke</i> , 2010, 41, 2894-2900.	2.0	134
24	Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load. <i>Hepatology</i> , 2012, 55, 68-76.	7.3	130
25	Role of Hepatitis B Virus Precore/Core Promoter Mutations and Serum Viral Load on Noncirrhotic Hepatocellular Carcinoma: A Case-€Control Study. <i>Journal of Infectious Diseases</i> , 2006, 194, 594-599.	4.0	125
26	Influence of Metabolic Risk Factors on Risk of Hepatocellular Carcinoma and Liver-Related Death in Men With Chronic Hepatitis B: A Large Cohort Study. <i>Gastroenterology</i> , 2017, 153, 1006-1017.e5.	1.3	123
27	Androgen-Receptor Gene CAG Repeats, Plasma Testosterone Levels, and Risk of Hepatitis B-Related Hepatocellular Carcinoma. <i>Journal of the National Cancer Institute</i> , 2000, 92, 2023-2028.	6.3	121
28	Body-Mass Index and Progression of Hepatitis B: A Population-Based Cohort Study in Men. <i>Journal of Clinical Oncology</i> , 2008, 26, 5576-5582.	1.6	119
29	The Asia-€Pacific Working Party on Non-€alcoholic Fatty Liver Disease guidelines 2017-€Part 2: Management and special groups. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 86-98.	2.8	117
30	Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. <i>Hepatology</i> , 2003, 37, 568-576.	7.3	111
31	Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma. <i>Gut</i> , 2007, 57, 91-97.	12.1	108
32	Epidemiology of HBV infection in Asian blood donors: Emphasis on occult HBV infection and the role of NAT. <i>Journal of Clinical Virology</i> , 2006, 36, S33-S44.	3.1	105
33	Transmission of occult hepatitis B virus by transfusion to adult and pediatric recipients in Taiwan. <i>Journal of Hepatology</i> , 2006, 44, 39-46.	3.7	105
34	Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers. <i>Gut</i> , 2015, 64, 292-302.	12.1	105
35	Hepatitis B viral factors in HBeAg-Negative carriers with persistently normal serum alanine aminotransferase levels. <i>Hepatology</i> , 2007, 45, 1193-1198.	7.3	103
36	Hepatitis B viral genotypes and lamivudine resistance. <i>Journal of Hepatology</i> , 2002, 36, 303-304.	3.7	102

#	ARTICLE	IF	CITATIONS
37	Polymorphisms in XRCC1 and Glutathione S-Transferase Genes and Hepatitis B-Related Hepatocellular Carcinoma. <i>Journal of the National Cancer Institute</i> , 2003, 95, 1485-1488.	6.3	100
38	Therapeutic implications of hepatitis B virus genotypes. <i>Liver International</i> , 2005, 25, 1097-1107.	3.9	100
39	Association of cytokine and DNA repair gene polymorphisms with hepatitis B-related hepatocellular carcinoma. <i>International Journal of Epidemiology</i> , 2005, 34, 1310-1318.	1.9	99
40	Quantitative hepatitis B core antibody levels in the natural history of hepatitis B virus infection. <i>Clinical Microbiology and Infection</i> , 2015, 21, 197-203.	6.0	98
41	RNA interference-mediated control of hepatitis B virus and emergence of resistant mutant. <i>Gastroenterology</i> , 2005, 128, 708-716.	1.3	97
42	Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV. <i>Gastroenterology</i> , 2018, 154, 989-997.	1.3	97
43	Role of reproductive factors in hepatocellular carcinoma: Impact on hepatitis B- and C-related risk. <i>Hepatology</i> , 2003, 38, 1393-1400.	7.3	96
44	Viral hepatocarcinogenesis: from infection to cancer. <i>Liver International</i> , 2008, 28, 175-188.	3.9	95
45	Effect of Host and Viral Factors on Hepatitis B E Antigen-Positive Chronic Hepatitis B Patients Receiving Pegylated Interferon- α 2A Therapy. <i>Antiviral Therapy</i> , 2011, 16, 629-637.	1.0	91
46	Pegylated Interferon- α 2a With or Without Low-Dose Ribavirin for Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Receiving Hemodialysis. <i>Annals of Internal Medicine</i> , 2013, 159, 729.	3.9	91
47	Association of chronic hepatitis B virus infection with insulin resistance and hepatic steatosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 779-782.	2.8	88
48	High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C. <i>Liver International</i> , 2008, 28, 271-277.	3.9	86
49	High Level of Hepatitis B Core-Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load. <i>Gastroenterology</i> , 2019, 157, 1518-1529.e3.	1.3	83
50	Long-term tracking of hepatitis B viral load and the relationship with risk for hepatocellular carcinoma in men. <i>Carcinogenesis</i> , 2008, 29, 106-112.	2.8	81
51	Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B. <i>Antiviral Therapy</i> , 2010, 15, 1133-1139.	1.0	80
52	Transient Elastography to Assess Hepatic Fibrosis in Hemodialysis Chronic Hepatitis C Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1057-1065.	4.5	77
53	Comparison of a 6-month course peginterferon α 2b plus ribavirin and interferon α 2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. <i>Journal of Viral Hepatitis</i> , 2005, 12, 283-291.	2.0	73
54	Pegylated interferon α -2a versus standard interferon α -2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. <i>Gut</i> , 2007, 57, 525-530.	12.1	69

#	ARTICLE	IF	CITATIONS
55	2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1135-1157.	1.7	69
56	A prospective study characterizing full-length hepatitis B virus genomes during acute exacerbation. <i>Gastroenterology</i> , 2003, 124, 80-90.	1.3	68
57	Hepatitis B Virus-related Hepatocellular Carcinoma: Epidemiology and Pathogenic Role of Viral Factors. <i>Journal of the Chinese Medical Association</i> , 2007, 70, 141-145.	1.4	67
58	Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients. <i>Gut</i> , 2013, 62, 182.2-184.	12.1	67
59	Distinct Relapse Rates and Risk Predictors After Discontinuing Tenofovir and Entecavir Therapy. <i>Journal of Infectious Diseases</i> , 2018, 217, 1193-1201.	4.0	67
60	Community and personal risk factors for hepatitis C virus infection: a survey of 23 820 residents in Taiwan in 1991-2. <i>Gut</i> , 2011, 60, 688-694.	12.1	66
61	Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up. <i>Hepatology</i> , 2013, 57, 2135-2142.	7.3	66
62	Permanent Inactivation of HBV Genomes by CRISPR/Cas9-Mediated Non-cleavage Base Editing. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 20, 480-490.	5.1	66
63	Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 7243-7248.	7.1	65
64	Serum adiponectin correlates with viral characteristics but not histologic features in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2005, 43, 235-242.	3.7	64
65	Circulating Programmed Death-1 as a Marker for Sustained High Hepatitis B Viral Load and Risk of Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2014, 9, e95870.	2.5	64
66	Taiwan consensus statement on the management of chronic hepatitis B. <i>Journal of the Formosan Medical Association</i> , 2019, 118, 7-38.	1.7	64
67	Comparison of Abbott RealTime HCV Genotype II with Versant Line Probe Assay 2.0 for Hepatitis C Virus Genotyping. <i>Journal of Clinical Microbiology</i> , 2015, 53, 1754-1757.	3.9	62
68	Molecular Mechanism and Treatment of Viral Hepatitis-Related Liver Fibrosis. <i>International Journal of Molecular Sciences</i> , 2014, 15, 10578-10604.	4.1	60
69	2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1019-1040.	1.7	60
70	Serum microRNA-122 level correlates with virologic responses to pegylated interferon therapy in chronic hepatitis C. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 7844-7849.	7.1	57
71	Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 3719-3724.	7.1	56
72	Impact of hepatitis B virus infection on metabolic profiles and modifying factors. <i>Journal of Viral Hepatitis</i> , 2012, 19, e48-57.	2.0	56

#	ARTICLE	IF	CITATIONS
73	Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence. <i>World Journal of Gastroenterology</i> , 2014, 20, 11384.	3.3	55
74	Insulin, glucose and hepatocellular carcinoma risk in male hepatitis B carriers: results from 17-year follow-up of a population-based cohort. <i>Carcinogenesis</i> , 2011, 32, 876-881.	2.8	53
75	Influences of tobacco and alcohol use on hepatocellular carcinoma survival. <i>International Journal of Cancer</i> , 2012, 131, 2612-2621.	5.1	52
76	Low incidence of hepatitis C virus transmission between spouses: A prospective study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 391-395.	2.8	51
77	Serum Hepatitis B Virus-DNA Levels Correlate With Long-term Adverse Outcomes in Spontaneous Hepatitis B e Antigen Seroconverters. <i>Journal of Infectious Diseases</i> , 2012, 205, 54-63.	4.0	51
78	Hepatitis B virus variants in patients receiving lamivudine treatment with breakthrough hepatitis evaluated by serial viral loads and full-length viral sequences. <i>Hepatology</i> , 2001, 34, 583-589.	7.3	50
79	Hepatitis B genotypes correlate with tumor recurrence after curative resection of hepatocellular carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 64-71.	4.4	50
80	Dual chronic hepatitis B virus and hepatitis C virus infection. <i>Hepatology International</i> , 2009, 3, 517-525.	4.2	49
81	Higher lifetime chance of spontaneous surface antigen loss in hepatitis B carriers with genotype C infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 949-960.	3.7	49
82	Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals. <i>Journal of Hepatology</i> , 2020, 72, 839-846.	3.7	49
83	Treatment of patients with dual hepatitis C and B by peginterferon α 2a and ribavirin reduced risk of hepatocellular carcinoma and mortality. <i>Gut</i> , 2014, 63, 506-514.	12.1	48
84	Young Chronic Hepatitis B Patients With Nucleos(t)ide Analogue-induced Hepatitis B e Antigen Seroconversion Have a Higher Risk of HBV Reactivation. <i>Journal of Infectious Diseases</i> , 2012, 206, 1521-1531.	4.0	47
85	Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion. <i>Hepatology</i> , 2013, 57, 934-943.	7.3	47
86	Host Genetic Factors Affecting Spontaneous HBsAg Seroclearance in Chronic Hepatitis B Patients. <i>PLoS ONE</i> , 2013, 8, e53008.	2.5	47
87	Long-term risk of tuberculosis in haematopoietic stem cell transplant recipients: a 10-year nationwide study. <i>International Journal of Tuberculosis and Lung Disease</i> , 2015, 19, 58-64.	1.2	47
88	HBsAg Profiles in Patients Receiving Peginterferon Alfa α 2a plus Ribavirin for the Treatment of Dual Chronic Infection with Hepatitis B and C Viruses. <i>Journal of Infectious Diseases</i> , 2010, 202, 86-92.	4.0	46
89	Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management. <i>Hepatology International</i> , 2013, 7, 316-326.	4.2	46
90	Increased risk of hepatocellular carcinoma in chronic hepatitis C patients with new onset diabetes: a nationwide cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 902-911.	3.7	46

#	ARTICLE	IF	CITATIONS
91	Development of risk scoring system for stratifying population for hepatocellular carcinoma screening. <i>Hepatology</i> , 2015, 61, 1934-1944.	7.3	46
92	Risk Stratification of Hepatocellular Carcinoma in Hepatitis B Virus e Antigen-“Negative Carriers by Combining Viral Biomarkers. <i>Journal of Infectious Diseases</i> , 2013, 208, 584-593.	4.0	45
93	Significance of definitions of relapse after discontinuation of oral antivirals in HBeAg-“negative chronic hepatitis B. <i>Hepatology</i> , 2018, 68, 415-424.	7.3	45
94	Asian consensus on the relationship between obesity and gastrointestinal and liver diseases. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1405-1413.	2.8	44
95	Fibrosis-4 Index Helps Identify HBV Carriers With the Lowest Risk of Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , 2017, 112, 1564-1574.	0.4	44
96	Genotypic dominance and novel recombinations in HBV genotype B and C co-infected intravenous drug users. <i>Journal of Medical Virology</i> , 2004, 73, 13-22.	5.0	43
97	Hepatitis B Virus Reactivation in Patients Receiving Interferon-Free Direct-Acting Antiviral Agents for Chronic Hepatitis C Virus Infection. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx028.	0.9	43
98	HEV superinfection accelerates disease progression in patients with chronic HBV infection and increases mortality in those with cirrhosis. <i>Journal of Hepatology</i> , 2020, 72, 1105-1111.	3.7	43
99	Precore/core promoter mutations and genotypes of hepatitis B virus in chronic hepatitis B patients with fulminant or subfulminant hepatitis. <i>Journal of Medical Virology</i> , 2004, 72, 545-550.	5.0	42
100	Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B. <i>Antiviral Therapy</i> , 2010, 15, 177-184.	1.0	42
101	Interferon α -2b with and without ribavirin in the treatment of hepatitis B e antigen-“positive chronic hepatitis B: A randomized study. <i>Hepatology</i> , 2006, 43, 742-749.	7.3	41
102	Vitamin D receptor gene polymorphisms and distinct clinical phenotypes of hepatitis B carriers in Taiwan. <i>Genes and Immunity</i> , 2010, 11, 87-93.	4.1	41
103	Interleukin 28B Genetic Polymorphisms and Viral Factors Help Identify HCV Genotype-1 Patients who Benefit from 24-Week Pegylated Interferon plus Ribavirin Therapy. <i>Antiviral Therapy</i> , 2012, 17, 477-484.	1.0	41
104	Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients: A pilot study. <i>Hepatology</i> , 2002, 36, 1416-1424.	7.3	41
105	Lamivudine treatment for hepatitis B reactivation in HBsAg carriers after organ transplantation: A 4-year experience. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2001, 16, 1001-1008.	2.8	40
106	Naturally occurring hepatitis B surface gene variants in chronic hepatitis B virus infection: Correlation with viral serotypes and clinical stages of liver disease. <i>Journal of Medical Virology</i> , 2002, 68, 50-59.	5.0	40
107	High prevalence of mixed genotype infections in hepatitis B virus infected intravenous drug users. <i>Journal of Medical Virology</i> , 2004, 74, 536-542.	5.0	40
108	Viral factors correlate with hepatitis B e antigen seroconversion in patients with chronic hepatitis B. <i>Liver International</i> , 2006, 26, 949-955.	3.9	40

#	ARTICLE	IF	CITATIONS
109	Hepatitis B genotypes and precore/basal core promoter mutants in HBeAg-negative chronic hepatitis B. <i>Journal of Gastroenterology</i> , 2002, 37, 283-287.	5.1	39
110	Natural Course and Treatment of Hepatitis D Virus Infection. <i>Journal of the Formosan Medical Association</i> , 2006, 105, 869-881.	1.7	39
111	Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naïve patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. <i>Gut</i> , 2015, 64, 303-311.	12.1	39
112	Hepatitis B Virus Core Variants Modify Natural Course of Viral Infection and Hepatocellular Carcinoma Progression. <i>Gastroenterology</i> , 2009, 137, 1687-1697.	1.3	38
113	Hepatitis C viral infection increases the risk of lymphoid neoplasms: A population-based cohort study. <i>Hepatology</i> , 2016, 63, 721-730.	7.3	38
114	Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection. <i>Journal of Clinical Investigation</i> , 2020, 130, 3205-3220.	8.2	38
115	Natural course and treatment of dual hepatitis B virus and hepatitis C virus infections. <i>Journal of the Formosan Medical Association</i> , 2005, 104, 783-91.	1.7	38
116	Serum Biomarkers Predictive of Significant Fibrosis and Cirrhosis in Chronic Hepatitis B. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 705-713.	2.2	37
117	Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease. <i>Gut and Liver</i> , 2021, 15, 451-458.	2.9	37
118	Genetic Variability of Hepatitis B virus and Response to Antiviral Therapy. <i>Antiviral Therapy</i> , 2008, 13, 613-624.	1.0	37
119	Pegylated Interferon Alfa-2a Monotherapy for Hemodialysis Patients with Acute Hepatitis C. <i>Clinical Infectious Diseases</i> , 2010, 51, 541-549.	5.8	36
120	Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy. <i>Antiviral Therapy</i> , 2009, 14, 45-54.	1.0	35
121	Association of Lipid Profiles With Hepatitis C Viral Load in Chronic Hepatitis C Patients With Genotype 1 or 2 Infection. <i>American Journal of Gastroenterology</i> , 2009, 104, 598-604.	0.4	34
122	The clinical significance of occult hepatitis B transfusion in Taiwan – a look-back study. <i>Transfusion Medicine</i> , 2011, 21, 33-41.	1.1	34
123	Metabolic profiles in patients with chronic hepatitis C: a case-control study. <i>Hepatology International</i> , 2008, 2, 250-257.	4.2	33
124	The ratio of aminotransferase to platelets is a useful index for predicting hepatic fibrosis in hemodialysis patients with chronic hepatitis C. <i>Kidney International</i> , 2010, 78, 103-109.	5.2	32
125	Increased risk for hepatitis B-related liver cirrhosis in relatives of patients with hepatocellular carcinoma in northern Taiwan. <i>International Journal of Epidemiology</i> , 2002, 31, 1008-1015.	1.9	31
126	High serum adiponectin correlates with advanced liver disease in patients with chronic hepatitis B virus infection. <i>Hepatology International</i> , 2009, 3, 364-370.	4.2	31

#	ARTICLE	IF	CITATIONS
127	Association of metabolic profiles with hepatic fibrosis in chronic hepatitis C patients with genotype 1 or 2 infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 970-977.	2.8	31
128	Fine mapping of hepatitis B virus pre- ϵ S deletion and its association with hepatocellular carcinoma. <i>Liver International</i> , 2012, 32, 1373-1381.	3.9	31
129	Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients: A pilot study. <i>Hepatology</i> , 2002, 36, 1416-1424.	7.3	30
130	Evolution of Hepatitis B virus in an acute hepatitis B patient co-infected with genotypes B and C. <i>Journal of General Virology</i> , 2006, 87, 39-49.	2.9	30
131	Influence of Metabolic Syndrome, Viral Genotype and Antiviral Therapy on Superimposed Fatty Liver Disease in Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2005, 10, 405-415.	1.0	30
132	Noninvasive Diagnosis of Hepatic Fibrosis in Patients With Chronic Hepatitis C by Splenic Doppler Impedance Index. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 1199-1206.e1.	4.4	29
133	Esophageal Varices: Noninvasive Diagnosis with Duplex Doppler US in Patients with Compensated Cirrhosis. <i>Radiology</i> , 2008, 248, 132-139.	7.3	29
134	Hepatitis B virus genotype B has an earlier emergence of lamivudine resistance than genotype C. <i>Antiviral Therapy</i> , 2009, 14, 1157-1163.	1.0	29
135	Chronic hepatitis B is associated with an increased risk of B-cell non-Hodgkin's lymphoma and multiple myeloma. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 589-598.	3.7	29
136	Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan. <i>Liver International</i> , 2021, 41, 1265-1277.	3.9	29
137	Androgen receptor exon 1 CAG repeat length and risk of hepatocellular carcinoma in women. <i>Hepatology</i> , 2002, 36, 156-163.	7.3	28
138	Hepatitis B Virus Basal Core Promoter Mutation and DNA Load Correlate with Expression of Hepatitis B Core Antigen in Patients with Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2009, 199, 742-749.	4.0	28
139	Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 710-717.	2.8	28
140	Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment. <i>Gut</i> , 2022, 71, 176-184.	12.1	28
141	Amebic Liver Abscess and Human Immunodeficiency Virus Infection. <i>Journal of Clinical Gastroenterology</i> , 2001, 33, 64-68.	2.2	27
142	Pegylated interferon α -2a plus low-dose ribavirin for the retreatment of dialysis chronic hepatitis C patients who relapsed from prior interferon monotherapy. <i>Gut</i> , 2009, 58, 314-316.	12.1	27
143	Serum cytokine/chemokine profiles in acute exacerbation of chronic hepatitis C: Clinical and mechanistic implications. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1629-1636.	2.8	27
144	Sofosbuvir-based Interferon-Free Direct Acting Antiviral Regimens for Heart Transplant Recipients With Chronic Hepatitis C Virus Infection. <i>Clinical Infectious Diseases</i> , 2018, 66, 289-292.	5.8	27

#	ARTICLE	IF	CITATIONS
145	Elimination of Hepatitis B in Highly Endemic Settings: Lessons Learned in Taiwan and Challenges Ahead. <i>Viruses</i> , 2020, 12, 815.	3.3	27
146	Smoking and Hepatitis B Virus-Related Hepatocellular Carcinoma Risk: The Mediating Roles of Viral Load and Alanine Aminotransferase. <i>Hepatology</i> , 2019, 69, 1412-1425.	7.3	26
147	Hepatitis C Virus and Hepatitis B Virus Co-Infection. <i>Viruses</i> , 2020, 12, 741.	3.3	26
148	High prevalence of occult hepatitis B virus infection in Taiwanese intravenous drug users. <i>Journal of Medical Virology</i> , 2007, 79, 1674-1678.	5.0	25
149	Incidence and risk analysis of aortic aneurysm and aortic dissection among patients with systemic lupus erythematosus: a nationwide population-based study in Taiwan. <i>Lupus</i> , 2014, 23, 665-671.	1.6	25
150	Nonalcoholic fatty liver disease: Updates in noninvasive diagnosis and correlation with cardiovascular disease. <i>World Journal of Gastroenterology</i> , 2014, 20, 7718.	3.3	25
151	Incorporating Serum Level of Hepatitis B Surface Antigen or Omitting Level of Hepatitis B Virus DNA Does not Affect Calculation of Risk for Hepatocellular Carcinoma in Patients Without Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 461-468.e2.	4.4	24
152	Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan. <i>Liver International</i> , 2020, 40, 758-768.	3.9	24
153	Evolution of precore/core promoter mutations in hepatitis B carriers with hepatitis B e antigen seroreversion. <i>Journal of Medical Virology</i> , 2004, 74, 237-245.	5.0	23
154	Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin. <i>Antiviral Therapy</i> , 2012, 17, 1059-1067.	1.0	23
155	Risk of extrathymic cancer in patients with myasthenia gravis in Taiwan: a nationwide population-based study. <i>European Journal of Neurology</i> , 2012, 19, 746-751.	3.3	23
156	Generic velpatasvir plus sofosbuvir for hepatitis C virus infection in patients with or without human immunodeficiency virus coinfection. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1690-1698.	3.7	23
157	Origin of serum hepatitis B virus in acute exacerbation: Comparison with HBV in the liver and from other exacerbation. <i>Hepatology</i> , 2004, 40, 310-317.	7.3	22
158	Clinicopathological differences between hepatitis B viral genotype B- and C-related resectable hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , 2007, 14, 64-69.	2.0	22
159	Milder clinical manifestation of scrub typhus in Kinmen, Taiwan. <i>Journal of the Formosan Medical Association</i> , 2013, 112, 201-207.	1.7	22
160	Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study. <i>Scientific Reports</i> , 2018, 8, 13699.	3.3	22
161	Updates on the treatment and outcomes of dual chronic hepatitis C and B virus infection. <i>World Journal of Gastroenterology</i> , 2014, 20, 2955.	3.3	22
162	Prevalence and clinical implications of HFE gene mutations (C282Y and H63D) in patients with chronic hepatitis B and C in Taiwan. <i>Liver International</i> , 2005, 25, 214-219.	3.9	21

#	ARTICLE	IF	CITATIONS
163	Increased incidence of gastroesophageal reflux disease in patients with chronic hepatitis B virus infection. <i>Hepatology International</i> , 2010, 4, 585-593.	4.2	21
164	Hepatitis B viraemia: its heritability and association with common genetic variation in the interferon γ signalling pathway. <i>Gut</i> , 2011, 60, 99-107.	12.1	21
165	Effects of hepatitis B virus precore and basal core promoter mutations on the expression of viral antigens: genotype B vs C. <i>Journal of Viral Hepatitis</i> , 2011, 18, e482-e490.	2.0	21
166	Treatment of patients with dual hepatitis $\langle \text{scp} \rangle \text{C} \langle / \text{scp} \rangle$ virus and hepatitis $\langle \text{scp} \rangle \text{B} \langle / \text{scp} \rangle$ virus infection: Resolved and unresolved issues. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 26-30.	2.8	21
167	Liver Gene Expression Profiles Correlate with Virus Infection and Response to Interferon Therapy in Chronic Hepatitis B Patients. <i>Scientific Reports</i> , 2016, 6, 31349.	3.3	21
168	Genome-wide identification of blood DNA methylation patterns associated with early-onset hepatocellular carcinoma development in hepatitis B carriers. <i>Molecular Carcinogenesis</i> , 2017, 56, 425-435.	2.7	21
169	Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment. <i>Journal of Viral Hepatitis</i> , 2020, 27, 568-575.	2.0	21
170	Asian Pacific association for the study of liver (APASL) guidelines: hepatitis B virus in pregnancy. <i>Hepatology International</i> , 2022, 16, 211-253.	4.2	21
171	Clinical aspects and outcomes of volunteer blood donors testing positive for hepatitis C virus infection in Taiwan: a prospective study. <i>Liver International</i> , 2003, 23, 148-155.	3.9	20
172	Characterization of interleukin 8 in woodchucks with chronic hepatitis B and hepatocellular carcinoma. <i>Genes and Immunity</i> , 2009, 10, 27-36.	4.1	20
173	Plasma Adipokines and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Virus "Infected Carriers: A Prospective Study in Taiwan. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1659-1671.	2.5	20
174	Synergistic Effect of Hyperglycemia and Helicobacter pylori Infection Status on Colorectal Adenoma Risk. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2744-2750.	3.6	20
175	Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan. <i>Hepatology International</i> , 2021, 15, 338-349.	4.2	20
176	Serum hepatitis B core-related antigen level stratifies risk of disease progression in chronic hepatitis B patients with intermediate viral load. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 908-918.	3.7	20
177	Combination Therapy for Chronic Hepatitis B: Current Updates and Perspectives. <i>Gut and Liver</i> , 2017, 11, 590-603.	2.9	20
178	A higher alanine aminotransferase level correlates with earlier hepatitis B e antigen seroconversion in lamivudine-treated chronic hepatitis B patients. <i>Liver International</i> , 2008, 28, 1034-1041.	3.9	19
179	Longitudinal Change of HBsAg in HBeAg-negative Patients with Genotype B or C Infection. <i>PLoS ONE</i> , 2013, 8, e55916.	2.5	19
180	Fibrosis F4 index predicts cirrhosis risk and liver-related mortality in 2075 patients with chronic HBV infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1480-1489.	3.7	19

#	ARTICLE	IF	CITATIONS
181	Decreased neonatal hepatitis B virus (HBV) viremia by maternal tenofovir treatment predicts reduced chronic HBV infection in children born to highly viremic mothers. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 306-316.	3.7	19
182	Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH). <i>American Journal of Gastroenterology</i> , 2020, 115, 1226-1235.	0.4	19
183	The non-structural 5A protein of hepatitis C virus exhibits genotypic differences in interferon antagonism. <i>Journal of Hepatology</i> , 2008, 49, 899-907.	3.7	18
184	Serum interleukin 6 level correlates with outcomes of acute exacerbation of chronic hepatitis B. <i>Hepatology International</i> , 2012, 6, 591-597.	4.2	18
185	Hepatitis B Surface Antigen Loss and Hepatocellular Carcinoma Development in Patients With Dual Hepatitis B and C Infection. <i>Medicine (United States)</i> , 2016, 95, e2995.	1.0	18
186	Acoustic Radiation Force Impulse US Imaging: Liver Stiffness in Patients with Chronic Hepatitis B with and without Antiviral Therapy. <i>Radiology</i> , 2018, 288, 293-299.	7.3	18
187	Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data. <i>Journal of Microbiology, Immunology and Infection</i> , 2020, 53, 569-577.	3.1	18
188	Long-Term Effect of Interferon Plus Ribavirin on Hepatitis B Surface Antigen Seroclearance in Patients Dually Infected with Hepatitis B and C Viruses. <i>PLoS ONE</i> , 2011, 6, e20752.	2.5	18
189	Early Viral Kinetics during Treatment of Chronic Hepatitis C Virus Infection with Pegylated Interferon Alpha plus Ribavirin in Taiwan. <i>Intervirology</i> , 2007, 50, 310-315.	2.8	17
190	Evidence for association with hepatocellular carcinoma at the PAPSS1 locus on chromosome 4q25 in a family-based study. <i>European Journal of Human Genetics</i> , 2009, 17, 1250-1259.	2.8	17
191	Consolidation therapy for HBeAg-positive Asian chronic hepatitis B patients receiving lamivudine treatment: a multicentre study. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2332-8.	3.0	17
192	Hyperglycemia combined with <i>Helicobacter pylori</i> infection increases risk of synchronous colorectal adenoma and carotid artery plaque. <i>Oncotarget</i> , 2017, 8, 108655-108664.	1.8	17
193	Decreased Colorectal Adenoma Risk After <i>Helicobacter pylori</i> Eradication: A Retrospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2019, 68, 2105-2113.	5.8	17
194	Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy. <i>Liver Cancer</i> , 2020, 9, 207-220.	7.7	17
195	Localization of a susceptibility locus for hepatocellular carcinoma to chromosome 4q in a hepatitis B hyperendemic area. <i>Oncogene</i> , 2006, 25, 3219-3224.	5.9	16
196	Lower serum viral loads in young patients with hepatitis-B-virus-related hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , 2007, 14, 153-160.	2.0	16
197	Hepatitis B surface antigen level complements viral load in predicting viral reactivation in spontaneous HBeAg seroconverters. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1242-1249.	2.8	16
198	Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients. <i>Scientific Reports</i> , 2017, 7, 3718.	3.3	16

#	ARTICLE	IF	CITATIONS
199	Mother-to-infant transmission of hepatitis B virus: challenges and perspectives. <i>Hepatology International</i> , 2017, 11, 481-484.	4.2	16
200	A noninvasive diagnosis of hepatic fibrosis by BioFibroScore® in chronic hepatitis C patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 291-297.	2.8	16
201	Pathologic findings of patients with nonalcoholic fatty liver disease and the impact of concurrent hepatitis B virus infection in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1476-1482.	1.7	16
202	Minimal role of GB virus-C/hepatitis G virus in fulminant and subfulminant hepatitis in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 14, 352-357.	2.8	15
203	Use of azathioprine for graft-vs-host disease is the major risk for development of secondary malignancies after haematopoietic stem cell transplantation: a nationwide population-based study. <i>British Journal of Cancer</i> , 2015, 112, 177-184.	6.4	15
204	Hepatitis B Core-Related Antigen Stratifies the Risk of Liver Cancer in HBeAg-Negative Patients With Indeterminate Phase. <i>American Journal of Gastroenterology</i> , 2022, 117, 748-757.	0.4	15
205	Overlap lamivudine treatment in patients with chronic hepatitis B receiving adefovir for lamivudine-resistant viral mutants. <i>Journal of Viral Hepatitis</i> , 2006, 13, 387-395.	2.0	14
206	Subgenotypes of hepatitis B virus genotype C do not correlate with disease progression of chronic hepatitis B in Taiwan. <i>Liver International</i> , 2007, 27, 983-988.	3.9	14
207	The risky body mass index ranges for significant hepatitis B viral load: A campus-based study. <i>Obesity Research and Clinical Practice</i> , 2012, 6, e31-e38.	1.8	14
208	Clinical and virological features of occult hepatitis B in patients with HBsAg seroclearance post-treatment or spontaneously. <i>Liver International</i> , 2014, 34, e71-9.	3.9	14
209	Clinical significance and evolution of hepatic HBsAg expression in HBeAg-positive patients receiving interferon therapy. <i>Journal of Gastroenterology</i> , 2014, 49, 356-362.	5.1	14
210	Perspectives on dual hepatitis B and C infection in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2016, 115, 298-305.	1.7	14
211	Impact of occult hepatitis B on the clinical outcomes of patients with chronic hepatitis C virus infection: A 10-year follow-up. <i>Journal of the Formosan Medical Association</i> , 2017, 116, 697-704.	1.7	14
212	Antiviral Therapy in Patients With Chronic Hepatitis C Is Associated With a Reduced Risk of Parkinsonism. <i>Movement Disorders</i> , 2019, 34, 1882-1890.	3.9	14
213	Sofosbuvir-based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1620-1625.	2.8	14
214	End-of-treatment virologic response does not predict relapse after lamivudine treatment for chronic hepatitis B. <i>World Journal of Gastroenterology</i> , 2004, 10, 3574.	3.3	14
215	Serum p53 gene polymorphisms and severity of hepatitis B or C-related chronic liver diseases in Taiwan. <i>Hepatology International</i> , 2011, 5, 814-821.	4.2	13
216	Peginterferon plus Ribavirin for HIV-infected Patients with Treatment-Naïve Acute or Chronic HCV Infection in Taiwan: A Prospective Cohort Study. <i>Scientific Reports</i> , 2015, 5, 17410.	3.3	13

#	ARTICLE	IF	CITATIONS
217	Progressive accumulation of mutations in the hepatitis B virus genome and its impact on time to diagnosis of hepatocellular carcinoma. <i>Hepatology</i> , 2016, 64, 720-731.	7.3	13
218	How Does Aging Affect Presentation and Management of Biliary Stones?. <i>Journal of the American Geriatrics Society</i> , 2016, 64, 2330-2335.	2.6	13
219	Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis. <i>Scientific Reports</i> , 2017, 7, 1728.	3.3	13
220	Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan. <i>PLoS ONE</i> , 2018, 13, e0209299.	2.5	13
221	<i>Helicobacter pylori</i> infection combined with non-alcoholic fatty liver disease increase the risk of atherosclerosis. <i>Medicine (United States)</i> , 2019, 98, e14672.	1.0	13
222	Association of Adjuvant Antiviral Therapy with Risk of Cancer Progression and Deaths in Patients with Hepatitis-B-Virus-Related Hepatocellular Carcinoma following Curative Treatment: A Nationwide Cohort Study. <i>PLoS ONE</i> , 2014, 9, e102051.	2.5	13
223	Sofosbuvir/Velpatasvir for Hepatitis B Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan. <i>Infectious Diseases and Therapy</i> , 2022, 11, 485-500.	4.0	13
224	A forgotten population with chronic hepatitis C infection: Subjects coinfecting with hepatitis B virus. <i>Hepatology</i> , 2004, 40, 266-266.	7.3	12
225	Differential Clinical and Virologic Impact of Hepatitis B Virus Genotypes B and C on HIV-Coinfected Patients Receiving Lamivudine-Containing Highly Active Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2012, 54, 548-555.	5.8	12
226	Clinical significance of circulating miR-122 in patients with dual chronic hepatitis B and C virus infection. <i>Hepatology International</i> , 2015, 9, 35-42.	4.2	12
227	Hepatic steatosis and development of type 2 diabetes: Impact of chronic hepatitis B and viral specific factors. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 1478-1487.	1.7	12
228	Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels. <i>Antiviral Therapy</i> , 2009, 14, 203-210.	1.0	12
229	Allergic rhinitis and risk of erectile dysfunction – a nationwide population-based study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2013, 68, 440-445.	5.7	11
230	Impact of Genetic Heterogeneity in Polymerase of Hepatitis B Virus on Dynamics of Viral Load and Hepatitis B Progression. <i>PLoS ONE</i> , 2013, 8, e70169.	2.5	11
231	Serum Mac-2-Binding Protein Glycosylation Isomer at Virological Remission Predicts Hepatocellular Carcinoma and Death in Chronic Hepatitis B-Related Cirrhosis. <i>Journal of Infectious Diseases</i> , 2020, 221, 589-597.	4.0	11
232	Profile and value of FIB-4 in patients with dual chronic hepatitis C and B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 410-417.	2.8	11
233	Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions. <i>Journal of the Formosan Medical Association</i> , 2019, 118, 556-564.	1.7	11
234	Early antiviral therapy reduces the risk of lymphoma in patients with chronic hepatitis C infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 331-339.	3.7	11

#	ARTICLE	IF	CITATIONS
235	Impact of PNPLA3 p.I148M and Hepatic Steatosis on Long-Term Outcomes for Hepatocellular Carcinoma and HBsAg Seroclearance in Chronic Hepatitis B. <i>Journal of Hepatocellular Carcinoma</i> , 2022, Volume 9, 301-313.	3.7	11
236	Functional impairment of dendritic cells in patients infected with hepatitis C virus genotype 1 who failed peginterferon plus ribavirin therapy. <i>Journal of Medical Virology</i> , 2011, 83, 1212-1220.	5.0	10
237	Clinical presentations of patients from different age cohorts with biliary tract stone diseases. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1614-1619.	2.8	10
238	Longitudinal change of metabolite profile and its relation to multiple risk factors for the risk of developing hepatitis B-related hepatocellular carcinoma. <i>Molecular Carcinogenesis</i> , 2020, 59, 1269-1279.	2.7	10
239	Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort). <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2884-2892.	2.8	10
240	Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis. <i>Journal of the Formosan Medical Association</i> , 2021, , .	1.7	10
241	Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy. <i>Antiviral Therapy</i> , 2009, 14, 45-54.	1.0	10
242	Lack of Interferon Sensitivity-Determining Region in the Genome of Hepatitis B Virus Genotype Ba. <i>Antiviral Therapy</i> , 2004, 9, 895-903.	1.0	10
243	Molecular cloning and expression of woodchuck granulocyte-macrophage colony stimulating factor. <i>Journal of Medical Virology</i> , 2001, 65, 567-575.	5.0	9
244	Kinetics of Hepatitis B Virus Reactivation After Chemotherapy: More Questions Than Answers. <i>Gastroenterology</i> , 2006, 131, 1656.	1.3	9
245	Patterns of managing chronic hepatitis B treatment-related drug resistance: a survey of physicians in Mainland China, South Korea, Taiwan, and Thailand. <i>Hepatology International</i> , 2009, 3, 453-460.	4.2	9
246	IL-21R Gene Polymorphisms and Serum IL-21 Levels Predict Virological Response to Interferon-Based Therapy in Asian Chronic Hepatitis C Patients. <i>Antiviral Therapy</i> , 2013, 18, 1-8.	1.0	9
247	Identification of a liver cirrhosis signature in plasma for predicting hepatocellular carcinoma risk in a population-based cohort of hepatitis B carriers. <i>Molecular Carcinogenesis</i> , 2014, 53, 58-66.	2.7	9
248	Consensus cost-effectiveness model for treatment of chronic hepatitis B in Asia Pacific countries. <i>Hepatology International</i> , 2014, 8, 382-394.	4.2	9
249	Viral Factors Affecting the Clinical Outcomes of Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2017, 216, S757-S764.	4.0	9
250	Expression of Metastatic Tumor Antigen 1 Splice Variant Correlates With Early Recurrence and Aggressive Features of Hepatitis B Virus-Associated Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 70, 184-197.	7.3	9
251	Whole genome deep sequencing analysis of viral quasispecies diversity and evolution in HBeAg seroconverters. <i>JHEP Reports</i> , 2021, 3, 100254.	4.9	9
252	Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 575-588.	8.9	9

#	ARTICLE	IF	CITATIONS
253	Changing epidemiology of liver disease in Asia: Dual infection of HBV and HCV. <i>Liver International</i> , 2022, 42, 1945-1954.	3.9	9
254	Hepatitis C virus reinfection in patients on haemodialysis after achieving sustained virologic response with antiviral treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, , .	3.7	9
255	Entecavir Prevents HBV Reactivation During Direct Acting Antivirals for HCV/HBV Dual Infection: A Randomized Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2800-2808.	4.4	9
256	Long-term Evolution of Estimated Glomerular Filtration Rate in Patients With Antiviral Treatment for Hepatitis C Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 424-434.e5.	4.4	9
257	Hepatocellular carcinoma after treatment cessation in non- ϵ irrhotic HBeAg- ϵ negative chronic hepatitis B: A multicentre cohort study. <i>Liver International</i> , 2022, 42, 541-550.	3.9	9
258	Subgenotypes of Hepatitis B Virus Genotype C in Taiwan. <i>Journal of Infectious Diseases</i> , 2005, 192, 1308-1309.	4.0	8
259	Mixed hepatitis B virus genotype infections: The more, the worse?. <i>Hepatology</i> , 2006, 44, 770-770.	7.3	8
260	Disease Progression in a Patient with Nonalcoholic Steatohepatitis. <i>Journal of the Formosan Medical Association</i> , 2008, 107, 816-821.	1.7	8
261	Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Na \tilde{v} e Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial. <i>Scientific Reports</i> , 2015, 5, 15255.	3.3	8
262	Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis. <i>Scientific Reports</i> , 2020, 10, 9180.	3.3	8
263	Serum cytokine/chemokine profiles predict hepatitis B reactivation in HBV/HCV co-infected subjects receiving direct-acting antiviral agents. <i>Journal of the Formosan Medical Association</i> , 2021, , .	1.7	8
264	Hepatitis B virus Quantification and Detection of YMDD Mutants in a Single Reaction by Real-Time PCR and Annealing Curve Analysis. <i>Antiviral Therapy</i> , 2008, 13, 469-480.	1.0	8
265	Dynamics of hepatitis B e antigen index ratio correlate with treatment response in chronic hepatitis B patients. <i>Liver International</i> , 2007, 27, 235-239.	3.9	7
266	Hepatitis B virus genotype: What should the clinician know?. <i>Current Hepatitis Reports</i> , 2007, 6, 17-23.	0.3	7
267	Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 102-109.	2.8	7
268	Peginterferon plus weight-based ribavirin for treatment-na \tilde{v} e hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trial. <i>Scientific Reports</i> , 2015, 5, 11710.	3.3	7
269	Advanced Hepatic Fibrosis and Steatosis Are Associated With Persistent Alanine Aminotransferase Elevation in Chronic Hepatitis C Patients Negative for Hepatitis C Virus RNA During Pegylated Interferon Plus Ribavirin Therapy. <i>Journal of Infectious Diseases</i> , 2015, 211, 1429-1436.	4.0	7
270	Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non- ϵ irrhotic hepatitis C virus genotype 1b patients receiving hemodialysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1977-1983.	2.8	7

#	ARTICLE	IF	CITATIONS
271	Evolution of estimated glomerular filtration rate in human immunodeficiency virus and hepatitis C virus coinfected patients receiving sofosbuvir-based direct-acting antivirals and antiretroviral therapy. <i>Journal of Viral Hepatitis</i> , 2021, 28, 887-896.	2.0	7
272	Molecular assays for hepatitis B virus infection. <i>Hepatology</i> , 2003, 38, 1311-1311.	7.3	6
273	Discontinuation of lamivudine treatment for hepatitis flare after kidney or heart transplantation in hepatitis B surface antigen-positive patients: A retrospective case series. <i>Clinical Therapeutics</i> , 2006, 28, 1327-1334.	2.5	6
274	Human leukocyte antigen-DRB1*1101 correlates with less severe hepatitis in Taiwanese male carriers of hepatitis B virus. <i>Journal of Medical Virology</i> , 2009, 81, 588-593.	5.0	6
275	Association of IL28B genotypes with metabolic profiles and viral clearance rate in chronic hepatitis C patients. <i>Hepatology International</i> , 2013, 7, 171-179.	4.2	6
276	Increased cancer risk in patients with haemophilia A: a nationwide population-based 14-year study in Taiwan. <i>Haemophilia</i> , 2014, 20, 741-746.	2.1	6
277	Prevalence and clinical implications of IL28B genotypes in Taiwanese patients with chronic hepatitis C. <i>Journal of the Formosan Medical Association</i> , 2016, 115, 953-960.	1.7	6
278	Increased risk of pulmonary tuberculosis in patients with gastroesophageal reflux disease. <i>International Journal of Tuberculosis and Lung Disease</i> , 2016, 20, 265-270.	1.2	6
279	High Risk of Clinical Relapse in Patients With Chronic Hepatitis B Virus Infection After Cessation of Prophylactic Antiviral Therapy for Rituximab-Containing Chemotherapy. <i>Journal of Infectious Diseases</i> , 2020, 222, 1345-1352.	4.0	6
280	Elbasvir/grazoprevir is effective and tolerable for the treatment of HCV GT1-infected patients: A real world multicenter observatory study in Taiwan. <i>Journal of Microbiology, Immunology and Infection</i> , 2021, 54, 588-595.	3.1	6
281	Twelve weeks of ledipasvir/sofosbuvir all-oral regimen for patients with chronic hepatitis C genotype 2 infection: Integrated analysis of three clinical trials. <i>Hepatology Research</i> , 2020, 50, 1109-1117.	3.4	6
282	Association of Lipid Profiles With Hepatitis C Viral Load in Chronic Hepatitis C Patients With Genotype 1 or 2 Infection. <i>American Journal of Gastroenterology</i> , 2009, 104, 598-604.	0.4	6
283	Effects of <i>Helicobacter pylori</i> infection in gastrointestinal tract malignant diseases: From the oral cavity to rectum. <i>World Journal of Gastrointestinal Oncology</i> , 2022, 14, 55-74.	2.0	6
284	Influence of metabolic syndrome, viral genotype and antiviral therapy on superimposed fatty liver disease in chronic hepatitis C. <i>Antiviral Therapy</i> , 2005, 10, 405-15.	1.0	6
285	Interferon-based therapy for dialysis patients with chronic hepatitis C: Progress and challenges (Editorial). <i>Nephrology</i> , 2007, 12, 8-10.	1.6	5
286	Core promoter mutations of hepatitis B virus and hepatocellular carcinoma: Story beyond A1762T/G1764A mutations. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 347-350.	2.8	5
287	HCV core gene polymorphisms correlate with liver fibrosis but not sustained virological response in patients with genotype 1 infection. <i>Antiviral Therapy</i> , 2011, 16, 227-235.	1.0	5
288	Associated factors and clinical implications of serum aminotransferase elevation in scrub typhus. <i>Journal of Microbiology, Immunology and Infection</i> , 2016, 49, 941-946.	3.1	5

#	ARTICLE	IF	CITATIONS
289	NOhep: Toward Global Control of Hepatitis B Virus Infection—An Introduction. <i>Journal of Infectious Diseases</i> , 2017, 216, S749-S749.	4.0	5
290	Antiviral therapy against chronic hepatitis C is associated with a reduced risk of oral cancer. <i>International Journal of Cancer</i> , 2020, 147, 901-908.	5.1	5
291	Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1871-1875.	1.7	5
292	Combined viral quasispecies diversity and hepatitis B core-related antigen predict off-nucleos(t)ide analog durability in HBeAg-negative patients. <i>Hepatology International</i> , 2021, 15, 582-592.	4.2	5
293	Rapid Prediction of Treatment Futility of Boceprevir with Peginterferon-Ribavirin for Taiwanese Treatment Experienced Hepatitis C Virus Genotype 1-Infected Patients. <i>PLoS ONE</i> , 2015, 10, e0137852.	2.5	5
294	Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up at 108 Weeks Posttreatment. <i>Clinical Infectious Diseases</i> , 2022, 75, 453-459.	5.8	5
295	Pegylated Interferons for the Treatment of Chronic Hepatitis B. <i>Recent Patents on Anti-infective Drug Discovery</i> , 2006, 1, 85-94.	0.8	4
296	Implications of Hepatitis B Virus Genomic Variations on Treatment Outcomes. <i>Current Pharmacogenomics and Personalized Medicine</i> , 2010, 8, 280-288.	0.2	4
297	Addition of ribavirin to daclatasvir plus asunaprevir for chronic hepatitis C 1b patients with baseline NS5A resistance-associated variants improved response. <i>Journal of the Formosan Medical Association</i> , 2017, 116, 295-299.	1.7	4
298	Boceprevir-based triple therapy to rescue HCV genotype 1/HBV dually infected patients refractory to peginterferon plus ribavirin combination therapy in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2018, 117, 497-504.	1.7	4
299	Limited drug-drug interaction of elbasvir/grazoprevir for chronic hepatitis C. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 933-940.	1.7	4
300	Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis. <i>Scientific Reports</i> , 2020, 10, 5372.	3.3	4
301	Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH). <i>Hepatology International</i> , 2021, 15, 1109-1121.	4.2	4
302	Characterization of metastatic tumor antigen 1 and its interaction with hepatitis B virus X protein in NF- κ B signaling and tumor progression in a woodchuck hepatocellular carcinoma model. <i>Oncotarget</i> , 2016, 7, 47173-47185.	1.8	4
303	Immunopathogenesis of Acute Flare of Chronic Hepatitis B: With Emphasis on the Role of Cytokines and Chemokines. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1407.	4.1	4
304	<i>Helicobacter pylori</i> infection and increased diabetes prevalence were the risks of colorectal adenoma for adults. <i>Medicine (United States)</i> , 2021, 100, e28156.	1.0	4
305	Reply. <i>Hepatology</i> , 2007, 46, 947-949.	7.3	3
306	Reactivation of hepatitis B virus in an inactive hepatitis B carrier with glucocorticoid pulse therapy. <i>Digestive and Liver Disease</i> , 2009, 41, 322-323.	0.9	3

#	ARTICLE	IF	CITATIONS
307	758 ENTECAVIR PLUS PEGINTERFERON alfa-2a vs. ENTECAVIR ALONE IN THE TREATMENT OF HEPATITIS B e ANTIGEN-POSITIVE CHRONIC HEPATITIS B: AN INTERIM REPORT. <i>Journal of Hepatology</i> , 2013, 58, S308.	3.7	3
308	Tu1502 â€“ Ledipasvir/Sofosbuvir is Highly Effective and Safe in Patients with Chronic Hepatitis B Virus and Hepatitis C Virus Coinfection: Final Study Results. <i>Gastroenterology</i> , 2019, 156, S-1345.	1.3	3
309	Relationship between serum gamma-glutamyl transferase level and colorectal adenoma. <i>PLoS ONE</i> , 2020, 15, e0240445.	2.5	3
310	Both hepatitis A and hepatitis D infections may be associated with more advanced liver disease in patients with chronic hepatitis B. <i>Advances in Digestive Medicine</i> , 2020, , .	0.2	3
311	Effects and safety of body positioning on back pain after transcatheter arterial chemoembolization in people with hepatocellular carcinoma: A randomized controlled study. <i>International Journal of Nursing Studies</i> , 2020, 109, 103641.	5.6	3
312	Long-term risk of end-stage renal diseases with maintenance dialysis among chronic hepatitis C patients after antiviral therapy in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2247-2254.	2.8	3
313	Investigating the prevalence and clinical effects of hepatitis delta viral infection in Taiwan. <i>Journal of Microbiology, Immunology and Infection</i> , 2021, 54, 901-908.	3.1	3
314	Gut-flora metabolites is not associated with synchronous carotid artery plaque and non-alcoholic fatty liver disease in asymptomatic adults. <i>Medicine (United States)</i> , 2021, 100, e27048.	1.0	3
315	Lack of interferon sensitivity-determining region in the genome of hepatitis B virus genotype Ba. <i>Antiviral Therapy</i> , 2004, 9, 895-903.	1.0	3
316	Hepatitis B virus quantification and detection of YMDD mutants in a single reaction by real-time PCR and annealing curve analysis. <i>Antiviral Therapy</i> , 2008, 13, 469-80.	1.0	3
317	Clinical Significance of Occult Hepatitis B Virus Infection Cannot Be Overlooked. <i>Clinical Infectious Diseases</i> , 2006, 42, 583-584.	5.8	2
318	Host genetic variants and hepatitis B virologic features in HBeAg-negative hepatitis B carriers with long-term biochemical remission. <i>Hepatology International</i> , 2012, 6, 598-605.	4.2	2
319	Micro-evolution of the hepatitis <sc>B</sc> virus genome in hepatitis <sc>B</sc> eâ€“antigenâ€“positive carriers: Comparison of genotypes <sc>B</sc> and <sc>C</sc> at various immune stages. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 172-177.	2.8	2
320	Immortal time bias in retrospective analysis: comment on â€“Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myelomaâ€“™. <i>Blood Cancer Journal</i> , 2015, 5, e283-e283.	6.2	2
321	Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4â€“6 infection: Real-world evidence from a nationwide registry in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 1567-1578.	1.7	2
322	Metabolic syndrome on top of chronic hepatitis B: the more, the worse?. <i>Gut</i> , 2010, 59, 276-277.	12.1	1
323	Transabdominal Ultrasound Finding and Acute Hepatocellular Injury in Different Cohorts of Elderly Adults with and without Common Bile Duct Stones. <i>Journal of the American Geriatrics Society</i> , 2013, 61, 1221-1224.	2.6	1
324	Commentary: treatment of hepatitis Câ€“related cirrhosis in the era of direct-acting anti-virals. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 1427-1428.	3.7	1

#	ARTICLE	IF	CITATIONS
325	Age and gender may be the key points in hyperglycemic patients with <i>Helicobacter pylori</i> infection combined colorectal adenoma. <i>Helicobacter</i> , 2018, 23, e12473.	3.5	1
326	Occult Hepatitis B Infection. , 2021, , 411-425.		1
327	Molecular Mechanisms and Animal Models of HBV-Related Hepatocellular Carcinoma: With Emphasis on Metastatic Tumor Antigen 1. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9380.	4.1	1
328	Kinetics of Hepatitis B Surface Antigen in Pregnant Women with and without Tenofovir Disoproxil Fumarate. <i>Journal of Viral Hepatitis</i> , 2021, , .	2.0	1
329	Sequential Combination Therapy for Chronic Hepatitis B: More Challenges to Be Tackled. <i>American Journal of Gastroenterology</i> , 2007, 102, 1544-1544.	0.4	0
330	Acute Fatty Liver of Pregnancy with Concurrent Acute Hepatitis B Virus Infection. <i>American Journal of Gastroenterology</i> , 2008, 103, 2663-2665.	0.4	0
331	Research Highlights: Pharmacogenomics of chronic hepatitis C. <i>Pharmacogenomics</i> , 2009, 10, 1039-1042.	1.3	0
332	Simple predictor for anemia in chronic hepatitis C patients receiving peginterferon plus ribavirin. <i>Advances in Digestive Medicine</i> , 2016, 3, 1-2.	0.2	0
333	A simple non-invasive test for ruling out cirrhosis in chronic hepatitis B. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 495-496.	8.1	0
334	Interspousal transmission of TT virus: Low efficiency and lack of apparent risk factors. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 1287-1291.	2.8	0
335	Treatment of Hepatitis C Virus Infection: Past, Present and Future. , 2012, , 341-371.		0